You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Contact a GSK Sales Representative

Chat with Medical Information

Go to Top Close

SYNFLORIX Dosing and Administration

Recommended dosing 1

Official recommendations in accordance with the Canadian Immunization Guide should be taken into account when immunizing with SYNFLORIX.

For alternative schedule for immunocompromising conditions or premature infants please consult the Product Monograph.

* First dose may be given as early as 6 weeks of age.
† The recommended time interval between doses is at least 1 month between primary doses for the 4 doses schedule
‡ An interval of 2 months between doses is recommended.
§ A booster dose is recommended at least 6 months after the last primary dose and may be given from the age of 9 months onwards.

Administration 1

SYNFLORIX should be given by intramuscular injection. The preferred sites are anterolateral aspect of the thigh in infants or the deltoid muscle of the upper arm in children.

SYNFLORIX should under no circumstances be administered intravascularly or intradermally.

SYNFLORIX can be given concomitantly with any of the following monovalent or combination vaccines [including DTPa-HBV-IPV/Hib]:

  • diphtheria-tetanus-acellular pertussis (DTPa)
  • hepatitis B (HBV)
  • inactivated polio (IPV)
  • Haemophilus influenzae type b (Hib)
  • measles-mumps-rubella (MMR)
  • varicella
  • meningococcal serogroup C conjugate (CRM197 and TT conjugates)
  • meningococcal serogroups A. C, W-135 and Y conjugate (TT conjugate)
  • rotavirus

Different injectable vaccines should always be given at different injection sites.

SYNFLORIX may be given to children with underlying immunocompromising conditions predisposed to invasive pneumococcal disease (such as sickle cell disease or HIV infection). Please consult the Product Monograph for complete dosing information in these patients.

References:

  1. Synflorix Product Monograph. GlaxoSmithKline Inc. August 31, 2018.

Français